Gain Therapeutics, Inc. (GANX) | Investment Case

1. Company Snapshot

1.a. Company Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.It focuses on rare genetic diseases and neurological disorders.The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.The company was founded in 2017 and is based in Bethesda, Maryland.

Show Full description

1.b. Last Insights on GANX

Gain Therapeutics' recent performance was driven by a series of positive developments, including the announcement of upcoming investor conferences, where Gene Mack, President and CEO, will present the company's progress. The company also presented preclinical data at the IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders, showcasing the potential of its lead candidate, GT-02287, in protecting dopaminergic neurons. Additionally, the company reported financial results for the first quarter of 2025, providing insight into its operational performance.

1.c. Company Highlights

Last Price	3.85
Change Percentage	10.00%
Open	3.52
Previous Close	3.5
Market Cap ( Millions)	139
Volume	2464016
Year High	3.98
Year Low	1.41
M A 50	2.29
M A 200	1.94

FCF Yield	-6.86%
Dividend Yield	0.00%
ROE	-289.11%
Debt / Equity	6.20%
Net Debt / EBIDTA	37.62%
Price To Book	31.61
Price Earnings Ratio	-6.28
Price To FCF	-14.58
Price To sales	1689.75
EV / EBITDA	-7.71

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov -20

Source: globenewswire.com

Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know

Nov -17

Source: zacks.com

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov -12

Source: globenewswire.com

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Nov -07

Source: seekingalpha.com

Gain Therapeutics to Present at Neuroscience 2025

Oct -30

Source: globenewswire.com

Gain Therapeutics Target of Unusually High Options Trading (NASDAQ:GANX)

Oct -23

Source: defenseworld.net

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct -16

Source: globenewswire.com

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Oct -09

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Therapeutics

Expected Growth: 10.5%

Growing demand for novel treatments of lysosomal storage diseases and CNS disorders, coupled with Gain Therapeutics' innovative brain-penetrant, small molecule allosteric modulators, drives market growth.

7. Detailed Products

Gain Therapeutics' Proprietary Brain-Targeted Technology

A novel, brain-targeted technology that enables the development of novel, brain-penetrant small molecule therapeutics for the treatment of CNS disorders.

Gain Therapeutics' Enzyme Enhancement Therapy (EET)

A proprietary, brain-targeted technology that enables the development of novel, brain-penetrant small molecule therapeutics that enhance enzyme activity for the treatment of lysosomal storage diseases.

Gain Therapeutics' Brain-Targeted Gene Therapy

A novel, brain-targeted gene therapy technology that enables the development of novel, brain-penetrant gene therapies for the treatment of CNS disorders.

8. Gain Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Gain Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for lysosomal storage diseases.

Bargaining Power Of Customers

Patients and healthcare providers have limited bargaining power due to the lack of effective treatment options for lysosomal storage diseases, giving Gain Therapeutics, Inc. an upper hand in pricing and negotiations.

Bargaining Power Of Suppliers

Gain Therapeutics, Inc. relies on a few key suppliers for raw materials and manufacturing services, giving them some bargaining power, but the company's strong financial position and diversified supply chain mitigate this risk.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants with innovative technologies and treatments for lysosomal storage diseases could potentially disrupt Gain Therapeutics, Inc.'s market share.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with multiple companies vying for market share and patent protection for their treatments, leading to a high intensity of rivalry among competitors.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	5.96%
Debt Cost	3.95%
Equity Weight	94.04%
Equity Cost	6.58%
WACC	6.42%
Leverage	6.34%

11. Quality Control: Gain Therapeutics, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Verve Therapeutics

A-Score: 4.4/10

Value: 6.8

Growth: 4.3

Quality: 5.0

Yield: 0.0

Momentum: 9.5

Volatility: 0.7

1-Year Total Return ->

ABVC BioPharma

A-Score: 4.2/10

Value: 6.2

Growth: 4.4

Quality: 4.3

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

Jaguar Health

A-Score: 3.2/10

Value: 9.6

Growth: 5.9

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

BioXcel Therapeutics

A-Score: 3.1/10

Value: 8.0

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Veru

A-Score: 2.9/10

Value: 6.6

Growth: 0.9

Quality: 4.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

Gain Therapeutics

A-Score: 2.2/10

Value: 6.0

Growth: 1.6

Quality: 3.5

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

16.90%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.42%

Gain Therapeutics, Inc. - US36269B1052

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on GANX

1.c. Company Highlights

Lower Quality

Lower Growth

Stable Momentum

Earnings Beats

Average Quality

Weak Momentum

Earnings Miss

Medium Volatility

Fairly Valued

Strong Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Therapeutics

Expected Growth: 10.5%

7. Detailed Products

Gain Therapeutics' Proprietary Brain-Targeted Technology

Gain Therapeutics' Enzyme Enhancement Therapy (EET)

Gain Therapeutics' Brain-Targeted Gene Therapy

8. Gain Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Gain Therapeutics, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.85$

Current Price

3.85$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA